Odisha News, Odisha Latest news, Odisha Daily - OrissaPOST
  • Home
  • Trending
  • State
  • Metro
  • National
  • International
  • Business
  • Feature
  • Entertainment
  • Sports
  • More..
    • Odisha Special
    • Editorial
    • Opinion
    • Careers
    • Sci-Tech
    • Timeout
    • Horoscope
    • Today’s Pic
  • Video
  • Epaper
  • News in Odia
  • Home
  • Trending
  • State
  • Metro
  • National
  • International
  • Business
  • Feature
  • Entertainment
  • Sports
  • More..
    • Odisha Special
    • Editorial
    • Opinion
    • Careers
    • Sci-Tech
    • Timeout
    • Horoscope
    • Today’s Pic
  • Video
  • Epaper
  • News in Odia
No Result
View All Result
OrissaPOST - Odisha Latest news, English Daily -
No Result
View All Result

Antiviral drug Umifenovir proves successful in treating COVID-19

Indo-Asian News Services
Updated: September 15th, 2021, 10:38 IST
in National, Prime News
0
Share on FacebookShare on TwitterShare on WhatsAppShare on Linkedin

Lucknow: The Central Drug Research Institute (CDRI) has claimed that the clinical trials of antiviral drug, Umifenovir, in treatment of Covid-19, have been a successful exercise.

The trial of Umifenovir on 132 Covid patients showed that, if proper dose is given twice daily for five days, the drug can effectively reduce viral load to zero in mild or moderate symptomatic and asymptomatic patients by checking multiplication of the virus.

Also Read

asaram

Rajasthan HC extends Asaram’s interim bail till July 9

5 hours ago
GST collections in Odisha

Gross GST collections rise 6.2 pc to over Rs 1.84 lakh cr in Jun

6 hours ago

Titled ‘Phase III, randomized, double-blind, placebo-controlled trial of efficacy, safety and tolerability of antiviral drug Umifenovir vs standard care of therapy in non-severe Covid-19 patients’, the clinical trial was conducted at three institutions – KGMU, Ram Manohar Lohia Institute of Medical Sciences (RMLIMS) and Era’s Lucknow Medical College and Hospital (ELMCH).

CDRI director Prof Tapas Kundu said, “Since Umifenovir is a broad-spectrum antiviral and is being used as a safe over-the-counter drug for influenza and pneumonia for over 20 years in Russia, China and other countries. The first two trials were not mandatory.”

The CDRI, therefore, directly went for phase-III trial, conducted on 132 patients either admitted in hospital or in home quarantine under the supervision of these hospitals,” the CDRI director said.

“In a study, double-blind mode improves reliability of results by preventing bias when doctors evaluate patient outcomes. The results showed that viral load in mild, moderate or asymptomatic patients after being given two doses of Umifenovir (800mg), twice a day, became zero in an average of five days. Patients did not experience any side-effects and their symptoms also did not turn severe,” he said.

Studies by CDRI in collaboration with CSIR-IMT, Chandigarh, also showed that Umifenovir exhibits good cell culture inhibition of SARSCov2, which suggests that the drug inhibits the entry of SARS-Cov2 virus into human cells.

Kundu said the institute was getting the dosage plan patented as it had not been used earlier for Covid-19.

“The Drug Controller General of India (DCGI) has evaluated the clinical trials report and in view of the highly encouraging results and he has asked the team to continue the studies on more mild, asymptomatic patients for grant of emergency approval of the drug,” he added.

CDRI chief scientist Prof R Ravishankar, who led the team, said, “Umifenovir will be economical for treating Covid-19 patients as it is around 54 per cent cheaper compared to current medication. The drug is safe for pregnant women and children. We are also looking into the possibility of Umifenovir syrup for children and also in powder form for puff inhalers.”

CDRI spokesperson Sanjeev Yadav said, “Umifenovir was selected from 16 drugs suggested by CSIR after looking into the feasibility of synthesis using locally available chemicals at the peak of the pandemic. DCGI then gave permission for trials in June last year.”

After securing ethical approvals and completing stability studies, the team took consent of patients and roped them in for the study.

 

Tags: CoronavirusCovidDrugsKGMULucknowUmifenovir
ShareTweetSendShare
Suggest A Correction

Enter your email to get our daily news in your inbox.

 

OrissaPOST epaper Sunday POST OrissaPOST epaper

Click Here: Plastic Free Odisha

#MyPaperBagChallenge

Debasis Mohanty

December 12, 2019
#MyPaperBagChallenge

D Rama Rao

December 12, 2019
#MyPaperBagChallenge

Smitarani Sahoo

December 12, 2019
#MyPaperBagChallenge

Tabish Maaz

December 12, 2019
#MyPaperBagChallenge

Shreyanshu Bal

December 12, 2019
#MyPaperBagChallenge

Praptimayee Biswal

December 12, 2019
#MyPaperBagChallenge

Anup Mahapatra

December 12, 2019
#MyPaperBagChallenge

Amritansh Mishra

December 12, 2019
#MyPaperBagChallenge

Anasuya Sahoo

December 12, 2019
#MyPaperBagChallenge

Archana Parida

December 12, 2019
#MyPaperBagChallenge

Swarit Praharaj

December 12, 2019
#MyPaperBagChallenge

Sarmistha Nayak

December 12, 2019
#MyPaperBagChallenge

Geetanjali Patro

December 12, 2019
#MyPaperBagChallenge

Pragyan Priyambada

December 12, 2019
#MyPaperBagChallenge

Archit Mohapatra

December 12, 2019
#MyPaperBagChallenge

Saishree Satyarupa

December 12, 2019
#MyPaperBagChallenge

Priyasha Pradhan

December 12, 2019
#MyPaperBagChallenge

Chinmay Kumar Routray

December 12, 2019
#MyPaperBagChallenge

Aishwarya Ranjan Mohanty

December 12, 2019
#MyPaperBagChallenge

Sisirkumar Maharana

December 12, 2019
#MyPaperBagChallenge

Pitabas Tripathy

December 12, 2019
#MyPaperBagChallenge

Rajashree Manasa Mohanty

December 12, 2019
#MyPaperBagChallenge

Pratik Kumar

December 12, 2019
#MyPaperBagChallenge

Adrita Bhattacharya

December 12, 2019
#MyPaperBagChallenge

Bijswajit Pradhan

December 12, 2019
#MyPaperBagChallenge

Subhajyoti Mohanty

December 12, 2019
#MyPaperBagChallenge

Arya Ayushman

December 12, 2019
#MyPaperBagChallenge

Faiza Firdous

December 12, 2019
#MyPaperBagChallenge

Mandakini Dakua

December 12, 2019
#MyPaperBagChallenge

Jyotshna Mayee Pattnaik

December 12, 2019

Archives

Editorial

New Democratic Face

Zohran Mamdani
July 1, 2025

US President Donald Trump, who had comfortably defeated his Democratic rival Kamala Harris in the recent presidential election and exuded...

Read more

Proof To Vote

Vote
June 30, 2025

Months ahead of the Assembly polls in Bihar, the Election Commission of India (ECI) on 28 June launched a ‘special...

Read more

Genesis of Jana Sangh

AAKAR PATEL
June 29, 2025

We marked the 50th anniversary of the Emergency a few days ago. Another anniversary, this time the 75th, went relatively...

Read more

Double-engine PMO

June 28, 2025

Since February, the Prime Minister’s Office (PMO) has been operating for the first time with two full principal secretaries, P.K....

Read more
  • Home
  • State
  • Metro
  • National
  • International
  • Business
  • Editorial
  • Opinion
  • Sports
  • About Us
  • Advertise
  • Contact Us
  • Jobs
Developed By Ratna Technology

© 2024 All rights Reserved by OrissaPOST

  • News in Odia
  • Orissa POST Epaper
  • Video
  • Home
  • Trending
  • Metro
  • State
  • Odisha Special
  • National
  • International
  • Sports
  • Business
  • Editorial
  • Entertainment
  • Horoscope
  • Careers
  • Feature
  • Today’s Pic
  • Opinion
  • Sci-Tech
  • About Us
  • Contact Us
  • Jobs

© 2024 All rights Reserved by OrissaPOST

    • News in Odia
    • Orissa POST Epaper
    • Video
    • Home
    • Trending
    • Metro
    • State
    • Odisha Special
    • National
    • International
    • Sports
    • Business
    • Editorial
    • Entertainment
    • Horoscope
    • Careers
    • Feature
    • Today’s Pic
    • Opinion
    • Sci-Tech
    • About Us
    • Contact Us
    • Jobs

    © 2024 All rights Reserved by OrissaPOST